Results 121 to 130 of about 158,415 (262)

Conceptualizing algorithmic inequality and future agenda. An annual review of information science and technology (ARIST) paper

Journal of the Association for Information Science and Technology, EarlyView.
Abstract The issue of inequality caused by algorithms, termed ‘algorithmic inequality’, has recently attracted scholarly attention in many disciplines due to its profound implications for society. While the body of literature on algorithmic inequality has grown, there remains a lack of comprehensive understanding of its nature, drivers, and impact ...
Shiwei Jia, Jia Tina Du, Hui Yan
wiley   +1 more source

Professional Independence as the Foundation of Modern Pharmacy Practice: A Comparative Analysis of Deontological Frameworks Across 30 European Jurisdictions. [PDF]

Healthcare (Basel)
Finta H, Chereches MC, Stroia IM, Șuteu-Albu A, Blaj SB, Muntean DL.   +5 more
europepmc   +1 more source

Electroconvulsive Therapy for Catatonia in Autistic and Non‐Autistic Patients: An Observational Study on Course, Efficacy, Aggression, and Self‐Injury Outcomes

Autism Research, EarlyView.
ABSTRACT Catatonia occurs disproportionately in autistic individuals and may respond to electroconvulsive therapy (ECT), yet prior reports suggest greater treatment burden in this population. We compared longitudinal ECT utilization, safety, and clinical outcomes between autistic and non‐autistic patients with catatonia.
Joshua Ryan Smith, Maria Bonnee, Sarah Marler, Seri Lim, D. Catherine Fuchs, Rafael Tamargo, Isaac Baldwin, Christopher Maley, Ashley VanHaverbeck, Courtney Hamilton, Timothy Adegoke, Haozheng Xu, Jinyuan Liu, Zachary J. Williams, Jo Ellen Wilson, James Luccarelli   +15 more
wiley   +1 more source

Autonomy without immunity: conventionality control and the limits of sporting sovereignty in the Inter-American system. [PDF]

Front Sports Act Living
Cruz-Núñez RL, Aguilar-Brito HA, Aguirre-Lanegra AJ, Seminario-Hurtado N.   +3 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

The patient statute (Law No. 15,378/2026) and the redefinition of medical authority: autonomy, dignity, and legal certainty at the bedside. [PDF]

Rev Assoc Med Bras (1992)
Cabar FR, Gaia BA.
europepmc   +1 more source

We ought to discuss the social construction of cadavers: Here's why and how

Anatomical Sciences Education, EarlyView.
Fatima Ehsan, Susan Lamb
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Legal regulation of conscientious objection to abortion in Australia: qualitative study among key interest-holders. [PDF]

Med Law Rev
Haining CM, Merner B, Willmott L, Savulescu J, Keogh LA.   +4 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source